BioVie Inc. Class A (BIVI)
NASDAQ: BIVIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BIVI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $8.58M
- EPS (TTM)
- -$2.85
- Dividend yield
- None
- 52-week range
- 0.7515 – 3.79
- Day range
- 0.7515 – 0.9104
- Volume / Avg
- 399.58K / 568.61K
- Beta
- —
- Shares outstanding
- 10.72M
- Next earnings
- Feb 5, 2027
52-week range
BIVI stock today
On Nov 20, BIVI ended the session at $0.80, shedding $0.1098 (12.07%), versus the S&P 500's 3.70% decline. At this level, BIVI sits near the bottom of its 52-week range of $0.7515 to $3.79: 78.9% below the high, set on Aug 12, 2026 and 6.5% above the low. BIVI is down 31.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 38.2%.
BioVie has posted a net loss over the last twelve months (EPS of -$2.85), so its P/E ratio is not meaningful. BioVie's next earnings report is expected on Feb 5, 2027.
Summary generated from market data by MetaCap's automated system. Methodology
About BioVie
Company profileBioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2b clinical trial to treat Parkinson's disease, as well as for the long COVID program.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Cuong Viet Do M.B.A.
- Headquarters
- Carson City, NV
- Employees
- 13
- Website
- bioviepharma.com
Financial highlights
Full financialsBioVie reported a net loss of $22.1 million, compared with a loss of $17.5 million a year earlier. Diluted earnings per share came in at -$3.05.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-22.07M | $-17.54M | $-32.12M | $-50.26M | $-26.08M |
| EPS (diluted) | $-3.05 | $-12.12 | $-73.05 | $-15.47 | $-1.06 |
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$5.26+557.50%
- Strong buy 0
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Feb 5, 2027
- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.68 vs —
BIVI news
All BIVI news- BioVie Presents New Biomarker Data Highlighting Biomarker-Defined Endotypes and Neuropeptide Y Response to Bezisterim at the 4th Long COVID International Conference 2026GlobeNewswire
- BioVie Presents New Biomarker Data from the ADDRESS-LC Trial of Bezisterim in Long COVID at the NIH RECOVER-TLC Third Annual WorkshopGlobeNewswire
- Fusion Power, Global Capital, Branded Streaming and Neurology Breakthroughs: New to The Street Show #779 Premieres Tonight on Bloomberg TelevisionBusiness InsiderCAST, BIVI
- BioVie Inc. Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private PlacementNasdaq
- BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesGlobeNewswire
- BioVie Selected for Late-Breaking Oral Presentation of Bezisterim Long COVID Data at the 4th Long COVID International Conference 2026GlobeNewswire
- BioVie's Bezisterim Shows Positive Signals In Long COVID Patients With Greater Symptom BurdenNasdaqBIVI, BRK.B
BioVie peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| OPTHOptimi Health Corp. | 1.51 | -13.71% | $8.65M | vs BIVI |
| LEXXLexaria Bioscience Corp. | 4.03 | -10.24% | $8.49M | vs BIVI |
| CALCCalciMedica Inc. | 1.26 | +7.69% | $8.69M | vs BIVI |
| HINDVyome Holdings Inc. | 1.20 | -17.24% | $8.42M | vs BIVI |
| QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares | 1.29 | -9.15% | $8.29M | vs BIVI |
| MBRXMoleculin Biotech Inc. | 7.74 | -2.40% | $8.22M | vs BIVI |
| PTNPalatin Technologies Inc. | 4.58 | -7.10% | $8.16M | vs BIVI |
| GDTCCytoMed Therapeutics Limited | 0.755 | -2.33% | $9.01M | vs BIVI |
Indexes, lists and sector
BioVie stock FAQ
What is BioVie's stock price today?
BIVI last traded at $0.80 as of Nov 20, 4:00 PM EST, down 12.07% on the day. Prices are delayed at least 15 minutes.
Does BioVie pay a dividend?
No. BioVie does not currently pay a regular cash dividend.
When is BioVie's next earnings date?
BioVie is expected to report earnings on Friday, February 5, 2027.
Who is BioVie's CEO?
Mr. Cuong Viet Do M.B.A. is the chief executive officer of BioVie Inc. Class A, which has about 13 employees.
Has BIVI ever split its stock?
Yes. The most recent BIVI stock split was a 1-for-10 split on Jul 7, 2025, one of 2 splits on record.
What is the BIVI 52-week high?
The 52-week high for BIVI is $3.79 and the 52-week low is $0.7515. The stock is currently 78.9% below its high.